GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Gross Profit

Synergy Pharmaceuticals (FRA:S90) Gross Profit : €22.00 Mil (TTM As of Sep. 2018)


View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Gross Profit?

Synergy Pharmaceuticals's gross profit for the three months ended in Sep. 2018 was €6.16 Mil. Synergy Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Sep. 2018 was €22.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Synergy Pharmaceuticals's gross profit for the three months ended in Sep. 2018 was €6.16 Mil. Synergy Pharmaceuticals's Revenue for the three months ended in Sep. 2018 was €9.52 Mil. Therefore, Synergy Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2018 was 64.68%.

Synergy Pharmaceuticals had a gross margin of 64.68% for the quarter that ended in Sep. 2018 => Durable competitive advantage

During the past 12 years, the highest Gross Margin % of Synergy Pharmaceuticals was 62.94%. The lowest was 47.62%. And the median was 47.62%.


Synergy Pharmaceuticals Gross Profit Historical Data

The historical data trend for Synergy Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals Gross Profit Chart

Synergy Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 6.77

Synergy Pharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 4.72 3.96 7.16 6.16

Competitive Comparison of Synergy Pharmaceuticals's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synergy Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's Gross Profit falls into.



Synergy Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Synergy Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2017 is calculated as

Gross Profit (A: Dec. 2017 )=Revenue - Cost of Goods Sold
=14.213 - 7.445
=6.77

Synergy Pharmaceuticals's Gross Profit for the quarter that ended in Sep. 2018 is calculated as

Gross Profit (Q: Sep. 2018 )=Revenue - Cost of Goods Sold
=9.517 - 3.361
=6.16

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Synergy Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2018 is calculated as

Gross Margin % (Q: Sep. 2018 )=Gross Profit (Q: Sep. 2018 ) / Revenue (Q: Sep. 2018 )
=(Revenue - Cost of Goods Sold) / Revenue
=6.16 / 9.517
=64.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Synergy Pharmaceuticals  (FRA:S90) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Synergy Pharmaceuticals had a gross margin of 64.68% for the quarter that ended in Sep. 2018 => Durable competitive advantage


Synergy Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Synergy Pharmaceuticals (FRA:S90) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170
Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines